{"id":"abbv-399","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, ABBV-399 allows T cells to recognize and attack cancer cells more effectively, leading to an enhanced anti-tumor response. This mechanism is thought to be responsible for the drug's ability to treat various types of cancer.","oneSentence":"ABBV-399 is a PD-1 inhibitor, a type of immunotherapy that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells more effectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:12.862Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT04928846","phase":"PHASE3","title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-03-25","conditions":"Non Small Cell Lung Cancer","enrollment":698},{"nctId":"NCT06568939","phase":"PHASE2","title":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-01-20","conditions":"Non-Small Cell Lung Cancer","enrollment":150},{"nctId":"NCT04830202","phase":"","title":"Expanded Access to Telisotuzumab Vedotin","status":"AVAILABLE","sponsor":"AbbVie","startDate":"","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT07323641","phase":"PHASE2","title":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-02-01","conditions":"Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT03539536","phase":"PHASE2","title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-10-10","conditions":"Non-small Cell Lung Cancer","enrollment":270},{"nctId":"NCT05513703","phase":"PHASE2","title":"A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2022-11-21","conditions":"Non Small Cell Lung Cancer","enrollment":9},{"nctId":"NCT02099058","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2014-01-15","conditions":"Advanced Solid Tumors Cancer","enrollment":237},{"nctId":"NCT06068842","phase":"","title":"A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-11-03","conditions":"Non Small Cell Lung Cancer","enrollment":579},{"nctId":"NCT06093503","phase":"PHASE3","title":"Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2024-05-31","conditions":"Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03574753","phase":"PHASE2","title":"Lung-MAP S1400K: c-MET Positive","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2018-03-16","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7","enrollment":28},{"nctId":"NCT03311477","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-06","conditions":"Advanced Solid Tumors Cancer","enrollment":9}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PERIPHERAL SENSORIMOTOR NEUROPATHY"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABBV-399","genericName":"ABBV-399","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABBV-399 is a PD-1 inhibitor, a type of immunotherapy that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells more effectively. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}